In a separate 12-month prospective study of 65 patients with type 2 diabetes mellitus (T2DM) initiating GLP-1 RA therapy (dulaglutide or semaglutide), significant reductions in body weight and BMI were also observed.71 Bone turnover markers and adiponectin levels increased, while myostatin decreased modestly. This evidence concerns the gene MSTN and type 2 diabetes mellitus.